Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VIGL

Vigil Neuroscience (VIGL) Stock Price, News & Analysis

Vigil Neuroscience logo

About Vigil Neuroscience Stock (NASDAQ:VIGL)

Key Stats

Today's Range
$8.05
$8.05
50-Day Range
$7.95
$8.08
52-Week Range
$1.75
$8.10
Volume
N/A
Average Volume
1.47 million shs
Market Capitalization
$383.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vigil Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel therapies to address neuroinflammation in debilitating neurodegenerative diseases. The company’s research centers on the TAM family of receptor tyrosine kinases, which regulate microglial activation and clearance processes in the central nervous system. By modulating these pathways, Vigil aims to slow or halt the progression of conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

Leveraging a proprietary discovery platform, Vigil identifies and optimizes small-molecule modulators with high specificity for TAM receptors and favorable brain penetration. Its lead candidates have demonstrated neuroprotective and anti-inflammatory effects in preclinical models and have progressed into early clinical development. Vigil plans to broaden its pipeline to additional indications where chronic neuroinflammation plays a key role.

Founded in 2019 and headquartered in New York City, Vigil Neuroscience is led by a team of seasoned professionals in neuroscience, drug discovery and clinical development. The company collaborates with academic institutions and industry partners and is supported by venture investors with deep expertise in life sciences, all with the shared goal of delivering transformative therapies for patients living with neurodegenerative disorders.

AI Generated. May Contain Errors.

Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VIGL Stock News Headlines

Vigil Neuroscience Inc Merger and Leadership Changes
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Headlines

VIGL Stock Analysis - Frequently Asked Questions

Vigil Neuroscience, Inc. (NASDAQ:VIGL) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04.

Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Thursday, January 6th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), ExxonMobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
5/07/2025
Today
8/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VIGL
CIK
1827087
Fax
N/A
Employees
40
Year Founded
2020

Profitability

EPS (Trailing Twelve Months)
($2.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$84.26 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-111.70%
Return on Assets
-74.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.97
Quick Ratio
2.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
4.60

Miscellaneous

Outstanding Shares
47,690,000
Free Float
39,099,000
Market Cap
$383.90 million
Optionable
Not Optionable
Beta
3.33

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:VIGL) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners